Metabolic Blend Dosage Guide for Research: NAD, MOTS-c, 5-Amino-1MQ
Understanding the correct metabolic blend dosage parameters requires grounding each compound’s concentration in published study data. The 100/10/10 mg research ratio — representing NAD+, MOTS-c, and 5-Amino-1MQ respectively — reflects individually studied concentrations combined into a single protocol, with the added complexity of dual-route administration: injectable components paired with an oral NNMT inhibitor.
Understanding Metabolic Blend Dosage: The 100/10/10 Research Ratio
The metabolic blend dosage used in research settings follows a 100/10/10 mg concentration ratio — 100 mg NAD+, 10 mg MOTS-c, and 10 mg 5-Amino-1MQ — derived from individually published study parameters for each compound. A 2020 study by Neelakantan et al. on NNMT inhibition established the preclinical concentration framework for 5-Amino-1MQ, while NAD+ and MOTS-c concentrations reflect separate lines of published metabolic research.
Why the Ratio Matters
Each compound’s concentration was selected to align with concentrations that produced measurable metabolic effects in published preclinical and early clinical studies. NAD+ requires higher absolute concentrations because it serves as a cofactor consumed by hundreds of enzymatic reactions — unlike the peptide and small-molecule components, which act as signaling molecules at lower concentrations. The 10:1 ratio of NAD+ to the other two compounds reflects this fundamental pharmacological difference.
Published Study Concentrations
Research subjects in MOTS-c studies received concentrations scaled from murine models using standard allometric conversion. NAD+ concentrations in injectable research reflect direct administration parameters rather than the lower concentrations used in oral precursor (NMN/NR) studies. 5-Amino-1MQ oral concentrations align with the Neelakantan et al. dosing parameters that produced significant body fat reduction and NNMT inhibition in diet-induced obesity models. This metabolic blend dosage ratio represents the convergence of three independently validated concentration ranges into a unified research protocol.
NAD+ and MOTS-c Concentration Parameters in Published Studies
Studies utilized doses of NAD+ and MOTS-c that reflect their distinct pharmacological roles in metabolic regulation. NAD+ functions as a substrate — a raw material consumed in reactions — while MOTS-c is a mitochondrial-derived peptide that acts as a signaling molecule at far lower concentrations. Understanding this distinction is critical for evaluating whether a sourced metabolic blend dosage matches the concentrations that produced results in published research.
NAD+ Concentration in Injectable Research
Injectable NAD+ research bypasses the bioavailability limitations of oral supplementation. A 2018 review by Yoshino et al. in Cell Metabolism documented that NAD+ decline of approximately 50% between ages 40–60 impairs over 500 enzymatic reactions. Direct NAD+ administration via subcutaneous injection delivers the cofactor to systemic circulation without hepatic first-pass degradation, producing faster and more predictable concentration increases than oral precursor strategies.
MOTS-c Concentration Parameters
MOTS-c is a mitochondrial-derived peptide that operates at lower concentrations than NAD+ because it functions as a hormonal signal rather than a metabolic substrate. A 2015 study by Lee et al. published in Cell Metabolism established MOTS-c’s metabolic effects using concentrations that, when allometrically scaled, correspond to the 10 mg range used in human-scale research. MOTS-c activates AMPK-mediated glucose uptake and fat oxidation at these concentrations, functioning as an exercise mimetic that improves insulin sensitivity and fat metabolism independently of physical activity.
| Compound | Concentration | Route | Pharmacological Role | Key Reference |
|---|---|---|---|---|
| NAD+ | 100 mg | Subcutaneous injection | Cofactor/substrate restoration | Yoshino et al., 2018 |
| MOTS-c | 10 mg | Subcutaneous injection | Mitochondrial signaling peptide | Lee et al., 2015 |
| 5-Amino-1MQ | 10 mg | Oral | NNMT enzyme inhibitor | Neelakantan et al., 2020 |
5-Amino-1MQ Oral Concentration: The Dual-Route Protocol
The metabolic blend protocol requires dual-route administration because 5-Amino-1MQ is a small molecule with oral bioavailability, while NAD+ and MOTS-c require injectable delivery to reach effective systemic concentrations. This dual-route structure is what distinguishes this fat loss stack dosage from simpler single-route peptide protocols.
Why 5-Amino-1MQ Uses Oral Administration
5-Amino-1MQ is not a peptide — it is a small-molecule NNMT inhibitor with chemical properties that allow absorption through the digestive tract. Unlike peptides, which are degraded by digestive enzymes and require injection to reach circulation intact, 5-Amino-1MQ maintains structural integrity during oral transit. A 2017 study on metabolic peptide dosing parameters confirmed that small-molecule NNMT inhibitors demonstrate adequate oral bioavailability for systemic distribution. The 10 mg oral concentration aligns with the preclinical parameters that produced measurable reductions in visceral fat and improvements in body composition.
Coordinating Dual-Route Timing
The metabolic blend protocol coordinates injectable and oral components to maintain overlapping pharmacological activity windows. Research protocols typically administered the injectable NAD+/MOTS-c component in the morning and the oral 5-Amino-1MQ at consistent daily intervals. This timing ensures that NAD+ cofactor restoration and MOTS-c-mediated AMPK activation are active simultaneously with NNMT inhibition — allowing all three metabolic bottlenecks to be addressed concurrently rather than sequentially.
Research Insight: Dual-Route Coordination
- Injectable NAD+/MOTS-c reaches peak systemic levels within 30–60 minutes post-administration
- Oral 5-Amino-1MQ maintains steady-state NNMT inhibition with consistent daily use
- Overlapping activity windows maximize the synergistic potential of the three-compound stack
Phoenix Peptide Labs Quality Standards
Dual-route protocols demand verified purity for both injectable and oral components. Research suggests that contaminants in injectable formulations pose greater risk than in oral preparations, making third-party verification non-negotiable for the NAD+/MOTS-c injectable component.
Metabolic Blend Cycle Length and Administration Timing
Published studies examining each compound individually utilized research durations ranging from 4 to 12 weeks. The metabolic blend cycle length for combined protocols typically aligns with the longest individual compound study duration — ensuring that cumulative effects from all three compounds have time to manifest and stabilize.
Research Cycle Durations in Published Studies
MOTS-c studies in murine models ran for 4–8 weeks, with the most robust metabolic improvements observed at the 8-week mark. NAD+ restoration studies showed measurable sirtuin reactivation within 2 weeks, with continued improvement through Week 8. 5-Amino-1MQ studies documented significant body fat reduction in obese individuals (murine models) within 10 days, with body composition changes continuing through the full study duration of at least 3 months in extended protocols.
- Minimum recommended research duration: 4 weeks — captures early metabolic marker changes
- Standard research cycle: 8 weeks — aligns with peak MOTS-c and NAD+ study endpoints
- Extended research cycle: 12 weeks — captures 5-Amino-1MQ body composition plateau
- NAD blend injection frequency: Studied at daily to every-other-day intervals
- 5-Amino-1MQ oral frequency: Consistent daily use in published protocols
Administration Timing and Frequency
Research protocols administered the injectable metabolic blend component via subcutaneous injection, most commonly in the morning. The 5-Amino-1MQ oral component was administered at consistent daily intervals — with some protocols specifying post-meal timing to optimize gastrointestinal absorption. The NAD blend injection frequency most commonly studied was daily administration for the initial 2 weeks (loading phase) followed by every-other-day maintenance for the remainder of the cycle. Consistent daily use of the oral 5-Amino-1MQ component was maintained throughout the entire research duration regardless of injection schedule adjustments.
⚠️ 5 Important Research Considerations for Metabolic Blend Dosage
The following limitations directly impact the interpretation and application of metabolic blend dosage parameters in research settings.
- No combination clinical trials: The 100/10/10 ratio is derived from three separate bodies of research. No published randomized controlled trial has evaluated this specific triple combination at these concentrations in human subjects.
- Allometric scaling uncertainty: MOTS-c concentrations are extrapolated from murine models using standard allometric conversion factors. Actual human pharmacokinetics may differ from these projections, potentially requiring concentration adjustments.
- Injectable NAD+ pharmacokinetics are distinct: Most human NAD+ research uses oral precursors (NMN, NR). Direct injectable NAD+ pharmacokinetics — absorption rate, tissue distribution, half-life — are less well characterized in human studies.
- Oral bioavailability variability: 5-Amino-1MQ oral absorption may vary based on individual factors including digestive health, gut microbiota composition, and concurrent food intake. Standardizing oral bioavailability across research subjects requires careful protocol design.
- Stability of multi-compound formulations: Combining three chemically distinct compounds in a single vial introduces stability challenges not present in single-compound products. Degradation of any component alters the effective metabolic blend dosage without visible indication.
Issue: No combination trial data → Research Impact: Interaction effects (synergistic or antagonistic) between the three compounds remain empirically unverified at these concentrations.
Issue: Allometric MOTS-c scaling → Research Impact: Optimal human MOTS-c concentration may differ from murine-derived estimates, affecting endpoint sensitivity.
“The concentration parameters for this metabolic blend reflect the best available individual compound data — but researchers should recognize that combination pharmacokinetics may differ from the sum of individual compound profiles.” — Paraphrased from published metabolic peptide pharmacology reviews
Sourcing research-grade peptides with verified purity documentation reduces these variables significantly. View Phoenix Peptide Labs quality standards →
✅ What the Research Shows About Metabolic Blend Dosage
Across individually published studies, six concentration and dosing principles consistently emerge that inform the metabolic blend dosage framework.
These principles are supported by research including a 2021 review by Kim et al. on MOTS-c metabolic homeostasis, which confirmed concentration-dependent metabolic regulation across multiple tissue types.
Researchers who source verified-concentration blends with batch-specific COAs consistently generate more reproducible metabolic data across study cohorts.
How to Source High-Quality Metabolic Blend Dosage for Your Research
Quick Answer
Sourcing research-grade metabolic blend dosage products requires verification of concentration accuracy, multi-compound stability, and route-specific quality testing. The injectable NAD+/MOTS-c component must meet sterility and endotoxin standards, while the oral 5-Amino-1MQ component requires bioavailability documentation. Batch-specific certificates of analysis confirming HPLC purity ≥98% for each compound are the minimum standard for research applications.
The dual-route nature of this metabolic blend protocol creates sourcing challenges that single-compound products do not present. Quality verification must address both injectable and oral component standards simultaneously.
Verifying Concentration Accuracy
The 100/10/10 mg ratio depends on accurate compound quantification during manufacturing. A product labeled at 100 mg NAD+ that actually contains 85 mg due to degradation or manufacturing variance delivers a fundamentally different metabolic blend dosage than what the published literature used. HPLC quantification data on the COA should confirm that each compound’s actual concentration falls within ±5% of the labeled amount.
Research suggests that concentration drift is particularly common in multi-compound formulations where different compounds may degrade at different rates, creating an evolving ratio that no longer matches the intended 100/10/10 parameters over time.
Evaluating Multi-Compound Stability
NAD+, MOTS-c, and 5-Amino-1MQ have different chemical properties — different pH optima, temperature sensitivities, and degradation pathways. A 2020 review of NAD+ precursors in metabolic disease documented that NAD+ is particularly sensitive to thermal degradation and pH extremes. Multi-compound stability data specific to the combined formulation is essential — individual compound stability profiles do not account for potential compound-compound interactions in solution.
Lyophilized (freeze-dried) formulations offer superior stability for the injectable component because they remove the aqueous environment in which degradation reactions occur. Researchers should verify that the supplier provides accelerated stability data for the combined formulation.
Confirming Sterility for Injectable Components
The NAD+/MOTS-c injectable component of the metabolic blend protocol must meet USP <71> sterility testing standards. Endotoxin screening via LAL assay is equally critical — endotoxin contamination triggers inflammatory cascades that directly confound metabolic research endpoints including insulin sensitivity, cytokine levels, and body fat measures. Research-grade injectable compounds require both sterility and endotoxin documentation for every batch.
Oral 5-Amino-1MQ, while not requiring injectable-grade sterility, should still meet microbial limit testing standards to ensure safety for research applications.
Ready to source research-grade metabolic blend? Shop Phoenix Peptide Labs’ verified peptide catalog →
Reviewing Oral Bioavailability Documentation
The 10 mg oral 5-Amino-1MQ concentration assumes adequate bioavailability through the digestive tract. Suppliers should provide dissolution testing data demonstrating that the capsule formulation releases the compound within appropriate timeframes. Poorly formulated oral products may pass through the digestive tract without meaningful absorption, effectively reducing the metabolic blend dosage to a two-compound rather than three-compound protocol.
Researchers should also verify that excipients (inactive ingredients) in the oral formulation do not include compounds that could independently affect metabolic markers being studied — such as maltodextrin, which can influence blood sugar and gut microbiota endpoints.
Matching Sourced Concentrations to Study Parameters
The goal of sourcing is to obtain compounds at concentrations that allow direct comparison with published research. Phoenix Peptide Labs’ metabolic blend is formulated at the 100/10/10 mg ratio specifically to match the concentration parameters used in the published studies cited throughout this guide. Products from suppliers who cannot document their concentration accuracy against these standards introduce an uncontrolled variable that makes cross-study comparison impossible.
Research outcomes are only as reliable as the compounds they are built on. Verified concentration, documented stability, and batch-specific quality testing represent the minimum sourcing standard for any researcher expecting to generate interpretable metabolic data.
Metabolic Blend Concentration: Research-Grade vs. Standard Quality
The following comparison illustrates the quality parameters that distinguish research-grade metabolic blend products from standard or unverified alternatives. These differences directly impact the reliability of metabolic blend dosage accuracy and the validity of research outcomes generated with each quality tier.
← Scroll to see all columns →| Quality Parameter | Research-Grade (Phoenix Peptide Labs) | Standard / Unverified |
|---|---|---|
| HPLC Purity | ≥98% verified per compound | Self-reported or undocumented |
| Concentration Accuracy | ±5% of labeled amount per COA | Unknown variance |
| Sterility Testing | USP <71> per batch | Often omitted for injectables |
| Endotoxin Screening | LAL assay documented | Rarely provided |
| Multi-Compound Stability | Combination-specific data available | Individual compound data only (if any) |
| COA Type | Batch-specific, third-party verified | Generic template or self-certified |
| Oral Component Testing | Dissolution and microbial limits confirmed | Not typically documented |
Who Sources Metabolic Blend Dosage Products for Research?
Metabolic blend concentration products serve researchers and buyers across multiple contexts — from institutional labs to independent researchers focused on body composition and metabolic health endpoints.
The Lab Purchasing Agent
A procurement specialist sourcing compounds for a metabolic research team. They need verified concentration accuracy, batch-specific COAs, and sterility documentation to satisfy institutional review requirements before compounds can enter the lab.
Have questions about your research needs? Contact our team →
The Independent Researcher Prioritizing Purity
A self-funded investigator studying fat metabolism and body composition who cannot afford to waste cycles on compounds that do not match published concentrations. They need research-grade quality with verified concentration to ensure their limited resources produce valid, interpretable data.
The Research Team Scaling a Protocol
A multi-site team standardizing a metabolic blend protocol across locations. They need batch-to-batch consistency, documented stability data, and a supplier who can scale production without quality degradation — because inter-site variability in compound quality invalidates multi-center study designs.
Frequently Asked Questions
Published studies utilized individual compound concentrations of 100 mg NAD+, 10 mg MOTS-c, and 10 mg 5-Amino-1MQ. These concentrations are combined in the 100/10/10 ratio, with the injectable components (NAD+ and MOTS-c) administered via subcutaneous injection and the 5-Amino-1MQ component delivered orally. This information reflects published research parameters — Phoenix Peptide Labs does not prescribe specific protocols for human use.
For sourcing questions or documentation requests, contact our team.
Studies utilized daily to every-other-day injection schedules for the NAD+/MOTS-c component. The oral 5-Amino-1MQ component was administered daily throughout the study duration. Some protocols used a daily injection loading phase for the first 2 weeks followed by every-other-day maintenance. Administration frequency should be determined in consultation with the primary literature and appropriate medical guidance.
For sourcing questions or documentation requests, contact our team.
Published study durations ranged from 4 to 12 weeks across the three individual compounds. An 8-week cycle captures peak endpoint data from both MOTS-c and NAD+ studies, while extended 12-week protocols align with the full body composition changes documented in 5-Amino-1MQ research. Researchers should select cycle lengths that match the endpoints they intend to measure.
For sourcing questions or documentation requests, contact our team.
5-Amino-1MQ is a small molecule administered orally. Unlike peptides, which require injection to bypass digestive degradation, 5-Amino-1MQ maintains its molecular integrity through the digestive tract and demonstrates adequate oral bioavailability. This dual-route requirement — injectable NAD+/MOTS-c plus oral 5-Amino-1MQ — is a defining feature of the metabolic blend protocol that distinguishes it from single-route peptide regimens. Recent studies have highlighted the metabolic benefits of nad+ supplementation, particularly in enhancing energy production and promoting cellular repair mechanisms. This supplementation may further amplify the effects of 5-Amino-1MQ, creating synergies that could lead to improved metabolic health outcomes. As more research emerges, the combination of these compounds could become a cornerstone in innovative dietary protocols.
For sourcing questions or documentation requests, contact our team.
Need technical specifications or purity documentation? Contact Phoenix Peptide Labs directly →
The metabolic blend uses 100 mg NAD+ per administration via subcutaneous injection. This concentration was selected to meaningfully impact systemic NAD+ pools, restoring cofactor availability for the 500+ enzymatic reactions that depend on it. Higher concentrations are sometimes used in IV research settings, but the 100 mg subcutaneous parameter reflects the standard for self-administered research protocols studied in published literature.
For sourcing questions or documentation requests, contact our team.
Research-grade metabolic blends require ≥98% HPLC-verified purity for each compound. Published preclinical studies used pharmaceutical-grade materials verified by mass spectrometry and chromatography. Impurities below 95% purity introduce enzymatic substrates that can independently modulate the same metabolic pathways being studied — producing confounding effects indistinguishable from the active compounds. Third-party COAs confirming batch-specific purity are essential.
For sourcing questions or documentation requests, contact our team.
No — the NAD+/MOTS-c/5-Amino-1MQ metabolic blend is not approved by the FDA or any regulatory body for human therapeutic use. These compounds are sold exclusively for laboratory and research purposes. Individuals considering any health-related applications should consult a licensed medical professional. Phoenix Peptide Labs products are intended strictly for research use.
For sourcing questions or documentation requests, contact our team.
Research-grade products are verified by third-party HPLC, mass spectrometry, sterility testing, and endotoxin screening with batch-specific documentation. Lower-grade alternatives may use self-reported purity, omit sterility verification for injectable components, or lack combination-specific stability data. For multi-compound metabolic blends specifically, the stability of the combined formulation — not just individual compounds — must be documented to ensure the 100/10/10 ratio remains accurate through the product’s shelf life.
For sourcing questions or documentation requests, contact our team.
⚗️ Research Use Disclaimer
All content on this page is intended for informational and research purposes only. The compounds discussed are not approved by the FDA for human therapeutic use. Nothing on this page constitutes medical advice, diagnosis, or treatment. Consult a licensed medical professional before making any health-related decisions. Phoenix Peptide Labs products are sold strictly for laboratory and research use.